You are here: Industry Insights > AstraZeneca

News List

AstraZeneca to sell drug rights to Covis Pharma in $371m deal pharmaceutical-technology
November 10, 2018
AstraZeneca has agreed to divest its rights for Alvesco (ciclesonide), Omnaris and Zetonna (ciclesonide) medicines to Swiss speciality pharmaceutical firm Covis Pharma in a deal valued up to $371m.
Deals this week: AstraZeneca, Yuhan, Bristol-Myers americanpharmaceuticalreviewpharmaceutical-technol
November 10, 2018
Covis Pharma currently markets the drugs in the US. The divestment will enable AstraZeneca to focus on the development of new and innovative drugs to fulfil the unmet needs of patients.
AstraZeneca Sells Rights to Alvesco, Omnaris and Zetonna to Covis Pharma americanpharmaceuticalreview
November 10, 2018
AstraZeneca has entered into an agreement with Covis Pharma to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated
AstraZeneca Sells Rights to Alvesco, Omnaris and Zetonna to Covis Pharma americanpharmaceuticalreview
November 10, 2018
AstraZeneca has entered into an agreement with Covis Pharma to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated
Divestment of rights to Alvesco, Omnaris and Zetonna to Covis Pharma worldpharmanews
November 10, 2018
AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal
AZ sells respiratory trio to Covis pharmatimes
November 09, 2018
Covis currently sells Alvesco, Omnaris and Zetonna in the US and will become the owner of the medicines. In return, it will pay AstraZeneca $350 million upon closing.
AZ books sales growth for the third quarter pharmatimes
November 09, 2018
AstraZeneca’s product sales returned to growth in the third quarter, with new medicines and emerging markets driving performance.
AstraZeneca's rummage sale continues with $350M deal, its second in a week fiercepharma
November 07, 2018
Only a week after AstraZeneca worked up a deal to sell some Nexium and Vimovo rights for hundreds of millions of dollars, the company is back at it with an agreement that’ll generate $350 million in cash.
AZ sheds Nexium, Vimovo rights to Gruenenthal pharmatimes
November 05, 2018
AstraZeneca is continuing to shed products outside the scope of its three core therapy areas with the sale of certain rights to Nexium...
AZ/MSD’s Lynparza assigned Orphan status in US pharmatimes
November 01, 2018
AstraZeneca and MSD’s PARP inhibitor Lynparza has been granted orphan drug designation in the US for the treatment of pancreatic cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page